Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.

Amelie WickmannMelina Sophie Kurte Julia JeckLuisa CamachoDennis Klinkhammer Florian Kron Robert Dengler

Published in: Cost effectiveness and resource allocation : C/E (2024)

Vinorelbine is most cost-effective, followed by SG. Health-economic evaluations support decision-makers to assess treatment options within one indication area. In Germany, the efficiency frontier can provide decision support for the pricing of innovative interventions. Results of our analysis may thus guide reimbursement determination.

Keyphrases

public health
healthcare
squamous cell carcinoma
small cell lung cancer
mental health
physical activity
decision making
randomized controlled trial
phase ii study
molecularly imprinted
health promotion
risk assessment
cell therapy
human health
open label
life cycle
data analysis